The second experimental arm testing tremelimumab added to Imfinzi and SoC recently completed, but did not meet its primary endpoint. Lurbinectedin could represent a potential new treatment for patients with SCLC, who have few options especially in the event of a relapse, and is being investigated in combination with doxorubicin as second-line therapy in a randomised phase 3 trial. AstraZeneca believes that IO-based therapies offer the potential for life-changing cancer treatments for the clear majority of patients. Annex 1 - Detailed information on conditional marketing authorisations 3. Tremelimumab is a human monoclonal antibody and potential new medicine that targets the activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Imfinzi in combination with etoposide and either carboplatin or cisplatin is currently under regulatory review for the treatment of ES-SCLC in the 1st-line setting based on the Phase III CASPIAN trial in the EU and Japan. 10. Conditional approval This medicine received a conditional marketing authorisation. 7. Please refer to your approved national product label (SmPC) for current product information. An extensive late-stage Immuno-Oncology programme focuses on lung cancer patients without a targetable genetic mutation which represents up to three-quarters of all patients with lung cancer.10 Imfinzi, an anti-PDL1 antibody, is in development for patients with advanced disease (Phase III trials POSEIDON and PEARL) and for patients in earlier stages of disease including potentially-curative settings (Phase III trials AEGEAN, ADJUVANT BR.31, PACIFIC-2, PACIFIC-4, PACIFIC-5, and ADRIATIC) both as monotherapy and in combination with tremelimumab and/or chemotherapy. Imfinzi is the only immunotherapy to show both a significant survival benefit and improved response rate in combination with chemotherapy for these patients, an important step forward in treating this devastating disease.”, Jonathan Goldman, MD, Associate Professor of Hematology & Oncology, UCLA Medical Center, Santa Monica, California and a lead investigator in the Phase III CASPIAN trial, said: “Patients with extensive-stage small cell lung cancer continue to face a poor prognosis, and finding new medicines to improve outcomes in this setting has been a formidable challenge. Although the European Medicines Agency's (EMA) offices will be closed from 18:30 on Wednesday 31 March until 07:30 on Tuesday 6 April 2021, remote working is still being enabled. Journal of Oncology Practice, volume 14, issue no. The CASPIAN trial met the primary endpoint of OS for Imfinzi plus chemotherapy in June 2019, reducing the risk of death by 27% versus chemotherapy alone. Imfinzi is also in development in the Phase II combination trials NeoCOAST, COAST and HUDSON in combination with potential new medicines from the early-stage pipeline. 1. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca. The safety and tolerability for Imfinzi plus SoC was consistent with the known safety profiles of these medicines. Personalized Therapy for Lung Cancer: Striking a Moving Target. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients with Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. AstraZeneca has a deep-rooted heritage in oncology and offers a quickly growing portfolio of new medicines that has the potential to transform patients' lives and the Company's future. Accessed March 2020. Enhertu can only be obtained with a prescription. It follows the recommendation for approval by the Committee for Medicinal Products for Human Use of the European Medicines Agency in July 2020. The approval by the Food and Drug Administration was based on positive results from the Phase III CASPIAN trial showing Imfinzi in combination with SoC platinum-etoposide demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus SoC alone. EGFR Mutation Testing in Lung Cancer: A Review of Available Methods and Their Use for Analysis of Tumour Tissue and Cytology Samples. 2013:66;79-89. Atezolizumab received FDA approval in March 2019 and EMA approval in July 2019, whereas durvalumab was approved by FDA in March 2020, both as first-line therapy for ED-SCLC []. Regarding safety, the immune-related adverse events (irAEs) from the chemo-immunotherapy in ES-SCLC had a mild impact on the overall toxicity, without any significant difference in grade 3–4 AEs as … As part of a broad development programme, Imfinzi is also being tested as a monotherapy and in combination with tremelimumab, an anti-CTLA4 monoclonal antibody and potential new medicine, as a treatment for patients with NSCLC, SCLC, bladder cancer, head and neck cancer, liver cancer, biliary tract cancer, cervical cancer and other solid tumours. Tremelimumab is being tested in a clinical trial programme in combination with Imfinzi in NSCLC, SCLC, bladder cancer, head and neck cancer and liver cancer. None had to be revoke… Emma Morriss. In addition to AstraZeneca's main capabilities, the Company is actively pursuing innovative partnerships and investments that accelerate the delivery of our strategy, as illustrated by the investment in Acerta Pharma in haematology. Imfinzi’s marketing application is centred on the results of the CASPIAN trial, which showed that adding the PD-L1 inhibitor to standard chemotherapy with etoposide and either cisplatin or carboplatin reduced the risk of death by 27 Protocol approval was obtained from an independent ethics committee at each site. 5. World Health Organization. In comparison, the control arm allowed up to six cycles of chemotherapy and optional prophylactic cranial irradiation. Shots: The P-III CASPIAN study involves assessing of Imfinzi + etoposide with cisplatin/carboplatin CT or Imfinzi + tremelimumab +CT vs CT as monothx. The CASPIAN trial enables clinicians to choose durvalumab in combination with etoposide and either carboplatin or cisplatin, making this an important new 1st-line treatment option for patients that is both effective and well-tolerated.”, The Phase III CASPIAN trial had two primary endpoints comparing experimental arms to SoC. Find all the latest news and updates published on this website in one place. Available at https://www.cancer.gov/publications/dictionaries/cancer-terms/def/small-cell-lung-cancer. EMA/511841/2020 Page 2/5 a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC were updated. Important notice for users Imfinzi approved in the US for extensive-stage small cell lung cancer, https://www.cancer.gov/publications/dictionaries/cancer-terms/def/small-cell-lung-cancer, http://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf, https://lungevity.org/for-patients-caregivers/lung-cancer-101/types-of-lung-cancer, https://www.cancer.net/cancer-types/33776/view-all. Intravenous durvalumab received US FDA accelerated approval in May 2017 for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing Dave Fredrickson, Executive Vice President, Head of the Oncology Business, said: “Patients in Europe diagnosed with locally-advanced, unresectable non-small cell lung cancer now have a new treatment option. Treatment Options for Relapsed Small-Cell Lung Cancer: What Progress Have We Made? Find out the latest on the safety profiles of COVID-19 vaccines from BioNTech, Moderna and AstraZeneca in our vaccine safety update reports, EMA’s human medicines committee (CHMP) has adopted several important recommendations that will increase manufacturing capacity and supply of COVID-19 vaccines in the EU, EMA’s human medicines committee (CHMP) recommended five medicines for approval at its 22-25 March 2021 meeting. You are about to access AstraZeneca historic archive material. 3. Annex 2 - Detailed information on unsuccessful conditional marketing authorisations 4. Details will be presented at a forthcoming medical meeting. Paz-Ares, L. et al. Keytruda already has approval for third-line SCLC treatment after the failure of chemotherapy and has a phase 3 trial as a first-line treatment nearing completion. A video recording and presentation slides are now available from EMA’s public meeting on COVID-19 vaccines on 26 March. Accessed March 2020. Upcoming first-time US approval decisions with priority review (to June) Conditional marketing authorisation - Report on ten years of experience at EMA 2. Lurbinectedin was active as second-line therapy for SCLC in terms of overall response and had an acceptable and manageable safety profile. It should be prescribed by a doctor and given under the supervision of a healthcare professional who has experience in the use of cancer medicines. 4. Our country sites can be located in the AZ Network. The approval is based on results from the Phase III PACIFIC trial. Results also showed an increased confirmed objective response rate in the Imfinzi plus SoC arm (68% versus 58% for SoC alone). Pakkala, S, et al. This was granted in the interest of public health because the medicine addresses an . Search for information on human, veterinary or herbal medicines. AstraZeneca PLC. 8. -. Czech PM says Sputnik V can be used not waiting for EMA approval In a couple of months other EU member states will want to have Sputnik V, said Andrej Babis Read more Defense firm … We aim to address the unmet needs of patients with EGFR-mutated tumours as a genetic driver of disease, which occur in 10-15% of NSCLC patients in the US and EU and 30-40% of NSCLC patients in Asia, with the approved medicines Iressa (gefitinib) and Tagrisso (osimertinib), and its ongoing Phase III trials ADAURA, LAURA, and FLAURA2.7-9 We are also committed to addressing tumour mechanisms of resistance through the ongoing Phase II trials SAVANNAH and ORCHARD which test Tagrisso in combination with savolitinib, a selective inhibitor of c-MET receptor tyrosine kinase, along with other potential new medicines. Additionally, it is approved in the US, the EU, Japan and several other countries around the world for the treatment of ES-SCLC based on the CASPIAN Phase III trial. Veeva ID: Z4-25396Date of next review: August 2022. As part of a broad development programme, Imfinzi is also being tested following concurrent chemoradiation therapy in patients with limited-stage SCLC in the Phase III ADRIATIC trial with data anticipated in 2021. AstraZeneca provides this link as a service to website visitors. The Russian jab is currently being assessed by Europe’s drug regulator, European Medicines Agency (EMA), which will decide whether the vaccine complies with efficacy, safety, and quality standards. We encourage you to read the privacy policy of every website you visit. Szumera-Ciećkiewicz A, et al. On March 27, 2020, the Food and Drug Administration approved durvalumab (IMFINZI, AstraZeneca) in combination with etoposide and either carboplatin or cisplatin as first-line treatment of … Monday, December 02, 2019. The approval was based on positive results from the Phase III CASPIAN trial of Imfinzi plus chemotherapy in ES-SCLC. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. “CASPIAN underlines the therapeutic value of chemoimmunotherapy in patients with [advanced] SCLC as a new standard of care,” wrote Thorsten Oliver Goetze, M.D., of the Institute of Clinical Cancer Research in Frankfurt, Germany, … The proposed indication is supported by study D419QC00001 (CASPIAN), an … Imfinzi is also approved for previously treated patients with advanced bladder cancer in the US and a small number of other countries. NCI Dictionary - Small Cell Lung Cancer. Find answers to the most frequently asked questions we receive. Lung cancer is the leading cause of cancer death among both men and women and accounts for about one fifth of all cancer deaths.4 Lung cancer is broadly split into non-small cell lung cancer (NSCLC) and SCLC, with about 15% classified as SCLC.5 About two thirds of SCLC patients are diagnosed with ES-SCLC, in which the cancer has spread widely through the lung or to other parts of the body.6 Prognosis is particularly poor, as only 6% of all SCLC patients will be alive five years after diagnosis.6. The approval by the Food and Drug Administration was based on positive results from the Phase III CASPIAN trial showing Imfinzi in combination with SoC platinum-etoposide demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus SoC alone. JCI Insight. Design Retrospective cohort study. ERC Belgium has asked the European Medicines Agency (EMA) to give conditional approval to its investigational anti-cancer vaccine Gliovac (ERC1671) for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. AstraZeneca has announced that Imfinzi (durvalumab) has been approved in the EU as a first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin. Ellison G, et al. 6 (June 1, 2018) 369-370. The CASPIAN trial results were presented in September at the World Conference on Lung Cancer (WCLC) in Barcelona, Spain, and published October 4 in The Lancet. National Cancer Institute. First published: 04/11/2020 EMA/423776 List item CHMP post-authorisation summary of positive opinion for Crysvita (II-10-G) (PDF/131.81 KB) EMA has published a 10-year report on its experience with conditional marketing authorisations, with data collected between July 2006 and June 2016: 1. For Media contacts, click here. Ustekinumab yesterday approved by EMA for patients with moderate to severe ptients with Ulcerative colitis! EGFR Mutation Testing on Cytological and Histological Samples in Non-Small Cell Lung Cancer: a Polish, Single Institution Study and Systematic Review of European Incidence. PIII trial CASPIAN found risk of death was reduced by 27% (equal to a hazard ratio of 0.73; p=0.0047), with median overall (OS) of 13.0 months for Imfinzi plus chemotherapy vs. 10.3 months for standard of care On March 18, 2019, the Food and Drug Administration approved atezolizumab (TECENTRIQ, Genentech Inc.) in combination with carboplatin and etoposide, for the first-line treatment of … Int J Clin Exp Pathol. EMA’s human medicines committee (CHMP) recommended five medicines for approval at its 22-25 March 2021 meeting Advice on use of ivermectin against COVID-19 COVID-19 | Treatments The trial was conducted in more than 200 centres across 23 countries, including the US, in Europe, South America, Asia and the Middle East. The most common Grade 3 or 4 adverse reaction (≥3%) was fatigue/asthenia (3.4%) In patients with extensive-stage SCLC in the CASPIAN study receiving IMFINZI plus chemotherapy (n=265), IMFINZI was discontinued due to adverse reactions in 7% of the patients receiving IMFINZI plus chemotherapy. 10-year report highlights During this period, 30 medicines received a conditional marketing authorisation. The Committee recommended granting a marketing authorisation for Copiktra (duvelisib) for the... Last week, EMA’s safety committee, PRAC, concluded its preliminary review of cases of blood clots, including very rare cases of blood clots with unusual features such as low numbers of platelets, in people vaccinated with Vaxzevria (previously COVID... EMA has reviewed the latest evidence on the use of ivermectin for the prevention and treatment of COVID-19 and concluded that the available data do not support its use for COVID-19 outside well-designed clinical trials. Types of Lung Cancer. For the United Kingdom, as of 1 January 2021, European Union law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland / NI. New manufacturing site for AstraZeneca’s COVID-19 vaccine A new manufacturing... Five new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended five medicines for approval at its March 2021 meeting. Available at https://www.cancer.net/cancer-types/33776/view-all. — Silvio Danese (@silvio_silvio75) You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. consisting of up to six cycles of CT and optional prophylactic cranial irradiation (PCI) in patients with extensive-stage SCLC in 22+ countries The P-III CASPIAN study results: median OS (13.0 vs 10.3 […] For details on how to contact the Investor Relations Team, please click here. Imfinzi is also approved for previously treated patients with advanced bladder cancer in the US and several other countries. CASPIAN wasn’t all positive for AZ however, as a combination arm looking at Imfinzi with experimental CTLA4 inhibitor tremelimumab and chemo – reported earlier this month – failed to show any benefit over chemo alone.